RNA vaccine technology is attracting attention to prevent COVID-19. When injected vaccine, it created antigens directly in the cell and stimulates immunity. RNA vaccine can be mass-produced in a short period of time and act as immune adjuvants.

Especially, the characteristic of our RNA vaccine technology is self-amplifying. Even if small doses are inoculated, it is effective enough, and there is no PEG component that causes allergies, so side effects can be minimized.

The most important technique in RNA vaccine is to deliver RNA into cells. Our RNA vaccine is protected by our LNP technology called LIONs(Lipid inorganic nanoparticles). It protects RNA and delivers RNA to cells without decomposing.

QTP104 is undergoing to Phase 1 clinical trial in South Korea.